7 Cambridge Center<br>Cambridge Massachusetts 02
320 Charles Street
About Broad InstituteThe Broad Institute was launched to pioneer a new model of collaborative biomedical science that would transform medicine. To accomplish these goals, we have built an amazing team of talented “Broadies” who work together to realize this transformation.
We are always looking for new Broadies to join our team and help us tackle important problems at the cutting edge of science.
The Broad community The Broad community includes professional scientists from many disciplines, administrative staff, and students. We seek to cultivate an interdisciplinary, goal-oriented work environment that unleashes scientific creativity and empowers our people to pursue ambitious and critical projects
Our work transcends traditional academic boundaries, giving Broad employees and affiliates access to an unparalleled biomedical research community across the Harvard and MIT communities and beyond.
Benefits of working at Broad The Broad Institute is committed to providing its employees with a competitive compensation and benefits package. We recognize the need for our employees to have a balance between work and personal life. To that end, our benefit plans and options reflect our desire to promote an environment that supports the health, diversity, and general wellbeing of our employees.
All Broadies also have access to world-class research and state of the art technology and are fully supported in their professional development, pushing the envelope for further growth.
The Broad Benefits Program includes:
• Medical • Dental • Basic Life Insurance, Accidental Death & Dismemberment, Business Travel and Supplemental Life Insurance • Short-Term and Long-Term Disability • Flexible Spending Accounts • 401(K) Plan w/Competitive Employer Match • 4 Weeks of Vacation after 1 Year • Tuition Reimbursement • Identity Theft Prevention and Insurance • Estate Planning • Adoption Assistance • Employee Assistance Program (EAP) • MBTA Commuter Transportation Subsidies • Parents in a Pinch Back Up Child Care • Credit Union
The Broad Institute is an equal opportunity employer.
To learn more about the Broad’s job opportunities, visit our Career Center at: https://www.broadinstitute.org/careers/career-center
136 articles with Broad Institute
A silicon wafer offers the powerful insights of the human genome for the low price of $100. Ultima Genomics CEO Gilad Almogy discussed the therapeutic possibilities with BioSpace.
A study by researchers at the Massachusetts Institute of Technolog (MIT) have found a brain circuit in the anterior thalamus that is critical for memory function.
David Sabatini, who was ousted last year by the Whitehead Institute over allegations of sexual harassment, may have found a new home at the NYU Grossman School of Medicine.
With $67 million in Series A financing, newly-launched Apertura plans to develop genetic medicines using technologies that address key limitations of gene delivery and expression.
Exo Therapeutics’ approach is not only different, it has revolutionary potential.
After allegations of bullying became public, Dr. Eric Lander, the director of the federal government’s Office of Science and Technology Policy, resigned from his executive branch role.
According to Politico, an internal White House investigation confirmed the alleged abuses from Lander, the president and founding director of the Broad Institute.
Arc begins its mission with $650 million in donations from donors. This funding will sustain the scientists and their researchers over renewable eight-year terms.
Newpath is guided by the ethos: “Do the right thing and good things will happen."
René Salazar joins Broad Institute as Chief Equity Officer
René Salazar has joined the Broad Institute of MIT and Harvard as its chief equity officer, a newly created position.
Broad announced that it is bringing René Salazar on board as its first chief equity officer.
Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research
Twist Bioscience to Offer Clinically Validated, Expert-Designed Exome Panel that Enriches Loci Relevant to Cancer, Rare and Inherited Diseases -
The massive genetic data mining project aims to gain deeper insight into how human genetic variants affect risk for common complex diseases.
Broad Institute granted FedRAMP authorization for Terra platform
FedRAMP certification enables federal agencies, or federally funded projects, to engage more deeply with the cloud computing system for handling sensitive data.
Eric Schmidt appointed incoming Chair of the Broad Institute Board of Directors
The Broad Institute of MIT and Harvard announced that renowned technologist, entrepreneur and philanthropist Eric Schmidt will become the next Chair of the Board of Directors, succeeding Louis V. Gerstner, Jr., who has served as Chair of the Board since 2013.
Broad Institute launches the Eric and Wendy Schmidt Center to connect biology, machine learning for understanding programs of life
Supported by a $150 million endowment from Eric and Wendy Schmidt, the center will create a new field of interdisciplinary research aimed at improving human health.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Broad Institute and Verily partner with Microsoft to accelerate the next generation of the Terra platform for health and life science research
Multiyear partnership brings together advanced technology, industry expertise and scale to help researchers interpret an unprecedented amount of biomedical data and derive insights to advance the treatment of human diseases
Broad Institute welcomes eight new members to its Cancer Dependency Map Consortium
The Broad Institute is expanding its Cancer Dependency Map Consortium, an academic-industrial partnership program that was first announced last year.
Color and Researchers from Massachusetts General Hospital and the Broad Institute Discover Key Finding to Determine Risk of Genomic Diseases
The research, published August 20 in Nature Communications, unveils the relationship between monogenic variants and polygenic risk for coronary artery disease, breast cancer, and colorectal cancer.